Media Room Menu
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Month Year
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Aug 6, 2020- Completed commercial-scale drug substance PPQ campaign ahead of schedule, enabling the expected on-time completion of the rolling Biologics License Application (BLA) submission for teplizumab in Q4 2020 -
-
Jul 31, 2020- Promising vaccine candidate selected by U.S. government’s Operation Warp Speed
-
Jul 30, 2020- Nirsevimab reduced respiratory syncytial virus (RSV) lower respiratory tract infections by 70 percent and related hospitalizations by 78 percent1
-
Jul 14, 2020* New alliance will use insights from translational and clinical studies to better identify targets, combinations and potential new indications for current medicines
-
Jun 19, 2020* Single-dose (300 mg) pre-filled pen provides additional administration option to adults and adolescents who are prescribed Dupixent
-
Jun 15, 2020-One Course of Teplizumab Now Shown to Delay Insulin-Dependent T1D by a Median of Approximately Three Years Compared to Placebo-
-
Jun 15, 2020- Preclinical data show anti-tumor activity in Sanofi's investigational compounds, including an oral selective estrogen receptor degrader (SERD) and an anti-CEACAM5 antibody-drug conjugate
-
Jun 14, 2020* Additional donation of factor therapy fulfills 2014 pledge to donate up to an unprecedented 1 billion IUs for humanitarian use
-
Jun 2, 2020Sarclisa added to carfilzomib and dexamethasone (Sarclisa combination) reduced risk of disease progression or death by 47% versus standard of care carfilzomib and dexamethasone (Kd) alone
-
May 29, 2020Across all groups combined, complete responses (CR) are now 16%; in the metastatic group with the longest follow-up, CRs are 20% representing a 200% increase over two years
-
May 26, 2020- In the pivotal trial, more than twice as many children achieved clear or almost clear skin and more than four times achieved itch reduction with Dupixent plus topical corticosteroids (TCS) compared to TCS alone
-
May 20, 2020- Nancy Wysenski, a Seasoned Pharmaceutical Executive with Rare Disease and Commercialization Experience, Appointed as a New Director -
-
May 18, 2020-- The preclinical prototype vaccine is well-tolerated and provides strong protection against coxsackievirus B infections and diabetes in relevant animal models
-
May 14, 2020Sutimlimab targets C1-activated hemolysis in cold agglutinin disease (CAD)
-
May 13, 2020- Emerging data demonstrate commitment to advancing cancer care, including two fully in-house investigational compounds: a potential best-in-class oral SERD for breast cancer and a first-in-class anti-CEACAM5 antibody-drug conjugate for non-small cell lung cancer
-
May 12, 2020- IKEMA trial results released early based on recommendation of an Independent Data Monitoring Committee
-
May 7, 2020- Company on Track to Complete Submission of Rolling Biologics License Application for Teplizumab in Q4 2020 -
-
May 5, 2020Objective responses seen in 29% of patients with locally advanced basal cell carcinoma (BCC)
-
Apr 27, 2020- Libtayo decreased the risk of death by 32.4% compared to chemotherapy
-
Apr 27, 2020• Independent Data Monitoring Committee recommended continuing ongoing Phase 3 trial only in the more advanced “critical” group with Kevzara higher-dose versus placebo and discontinuing less advanced “severe” group
-
Apr 24, 2020Latest innovation in quadrivalent meningococcal vaccination designed for use in persons 2 years of age and older in the U.S.
-
Apr 23, 2020Primary and secondary objectives were met with 85% or greater relative reduction achieved in the number of new gadolinium-enhancing T1 and new or enlarging T2 hyperintense lesions
-
Apr 16, 2020- Companies to negotiate a collaboration on the development of a breakthrough COVID-19 self-test solution based on Luminostics’ proprietary technology.
-
Apr 16, 2020- Rolling BLA Submission Initiated Under Breakthrough Therapy Designation
-
Apr 14, 2020Companies to combine innovative technologies to develop an adjuvanted COVID-19 vaccine
-
Apr 9, 2020The award showcases innovative game-changers who are setting the standard for pharmaceutical facilities of the future
-
Apr 3, 2020- Detailed data to be presented at the Revolutionizing Atopic Dermatitis Conference show adding Dupixent to topical corticosteroids improved skin clearance; average overall disease improved by approximately 80%
-
Mar 27, 2020* The two companies will jointly investigate multiple candidates with the goal of advancing an efficacious and safe SARS-CoV-2 vaccine into clinical development
-
Mar 16, 2020- PROTECT Study Randomization to be Paused Temporarily in Response to the Ongoing Public Health Crisis
-
Mar 16, 2020* U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately
-
Mar 12, 2020- Expect to Complete Submission of a BLA for PRV-031 (Teplizumab) in Q4 2020
-
Mar 12, 2020-PRV-3279 Inhibited the Function of B Cells, Durably and Without Depletion-
-
Mar 2, 2020* Sarclisa in combination with pomalidomide and dexamethasone (pom-dex) significantly reduced the risk of disease progression or death by 40% compared to pom-dex alone in a pivotal trial
-
Feb 19, 2020
-
Feb 18, 2020- Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi's well-established recombinant technology platform to expedite a potential COVID-19 vaccine